Experimental drug for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called B-cell NHL that has come back or not responded to previous treatment.
- You have had at least two prior cancer treatments, including a treatment that targets CD20 (like rituximab).
- You must have disease that can be measured on scans.
- You are able to take care of yourself (ECOG performance status 0-2).
- Your organs (like kidneys, liver, heart) must be working well enough for the study drug.
- You cannot have untreated or active involvement of lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.